Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Retrieved on:
Dienstag, September 12, 2023
Linda, SAB, Special Program of Assisted Reproduction, Biotechnology, Northwest Biotherapeutics, OTCQB, United States Air Force Scientific Advisory Board, MBA, Research, Doctor of Philosophy, Brain, Glioblastoma, Professor, Journal, National academy, Buenos Aires National Academy of Medicine, MD, Journal of Neuro-Oncology, Biology, Knowledge, Principal, UCLA, Centers of Biomedical Research Excellence, Medical imaging, Medical device
BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
Key Points:
- BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
- Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma.
- She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program.
- Linda Powers, NWBio CEO, commented: "We are delighted to have Dr. Liau join our existing distinguished SAB.